Why We Love Wild Penny Stocks

Recs

31

Penny stocks have huge potential -- that's their blessing and their curse.

The potential rewards are enormous. Just look at the returns from Generex Biotechnology (Nasdaq: GNBT) and MIVA (Nasdaq: MIVA), each of which have quickly doubled this month.

Those $0.10 doubles look like easy gains, considering that Wesco Financial (NYSE: WSC) would have to add another $267 in value to double its share price, and NVR (NYSE: NVR) would need to throw another $380 on the fire to eke out a double from here.

Everybody loves pennies
It's the potential of quick gains in "cheap" stocks that keeps investors coming back. We typed "penny stocks" into Google, and the search engine spat out "about 2,750,000" hits. We did the same for more time-tested terms such as "blue-chip stocks" and "dividend stocks" and got just 2,080,000 and 369,000 hits, respectively -- and we should note that those numbers have increased substantially over the past few weeks, as downside volatility has wracked the market.

The search became even more interesting when we broke down those hits with Google Trends. According to Trends, penny stocks are particularly alluring to investors in Las Vegas, Tampa, and Orlando -- the locales where the term is most often searched.

Las Vegas, for one, makes a bit of sense. The folks there are gamblers.

Florida, though? Well, we hope the folks Googling "penny stocks" down there aren't retirees.

This stock is set to take off! Or not ...
According to the Securities and Exchange Commission, the term "penny stock" generally refers to low-priced (typically less than $5), speculative securities of very small companies. To quote the SEC: "Investors in penny stocks should be prepared for the possibility that they may lose their whole investment." (It's worth noting that the emphasis in that last sentence is in the original.)

Pay attention to the SEC's entire definition, not just the stock price. Going solely on price would wrongly categorize billion-dollar companies such as Dynegy (NYSE: DYN) and Qwest (NYSE: Q) as penny stocks.

Regardless, the SEC is spot-on when it says that investing in true penny stocks is among the surest ways to lose money in the stock market.

Well, then, why do we love penny stocks?
We love penny stocks because they're fascinating. The world of pennies is inhabited by hardworking average Joes hoping to strike it rich, as well as by pumpers and dumpers, hypesters and scammers. In pennies, the logic and reason that applies in the rest of daily life is replaced by zeal and prayer.

However, we don't love them enough to actually buy them. Yes, they have big potential, but their daily gyrations are unpredictable -- the stock price movements have next to nothing to do with the underlying company the stock represents. In fact, trading in pennies is highly illiquid, and prices are often manipulated by forces not at all related to the business.

The dangers of incredible promises
If you're buying stocks without paying attention to the business you're buying, then you might as well be buying a lottery ticket. Or, to use another analogy, you might as well buy up every baseball card of a benchwarmer on the Akron Aeros AA baseball team and hope that he someday rises up, fulfills his potential, and becomes an all-star for the big-league Cleveland Indians.

There's a better way
Before you start saying the rest of the stock market is boring -- with big stocks such as IBM having a "big day" when they move up 1% or so -- let us introduce you to some underfollowed small caps. They're nothing like penny stocks, yet they still offer some of the best returns on the market. Unlike penny stocks, promising small caps:

  • File reliable financial statements.
  • Are transparent.
  • Have conference calls that individual investors can listen to.
  • Don't simply hype their stock in press releases.

That's a starting point. There are more -- and more important -- criteria to help you find great small-cap companies. Our team at Motley Fool Hidden Gems, for instance, looks for a balance sheet with lots of cash and no debt, and a tenured CEO (or founder, if possible) who holds a substantial ownership stake in the business. In other words, we're looking for big returns with good old-fashioned bottom-up analysis.

You can view the more than 50 small caps our team has already found by taking a free 30-day trial. There's no obligation to subscribe, and we particularly recommend it for the penny-stock-o-philes reading in Vegas and Florida. You know who you are.

This article was originally published July 27, 2006. It has been updated.

Tim Hanson and Brian Richards disagree about whether the U.S. Treasury should do away with the penny. Neither owns shares of any company mentioned. The Fool's disclosure policy is finger-lickin' good.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 14, 2009, at 10:43 AM, moneymotto wrote:

    i think any one with an extra 100 to200 dallors a month resturant habit,could gamble on penney stocks and have a little fun. i have made several thousand dollars and lost alittle extra bagage, that"s right.!!

  • Report this Comment On March 15, 2009, at 6:04 PM, zapzinger wrote:

    Hanson and Richards make a good point about the potentially huge returns of Generex (GNBT).

    As Fool observed in July 11, 2007, in More Than Momentum: Stocks Rising for a Reason, "Investors seem most excited by the prospects for Generex's oral insulin product, which will start phase 3 trials later this year, with possible marketing approval by late 2009....intrigued enough by the promise hiding in the pipeline of drug-delivery solutions for diabetes to weigh in on the bullish side. Thirty-six of the 40 CAPS All-Stars who've rated the stock believe it will outperform the market going forward."

    Last week's 350% jump, prompted by Generex reporting excellent Phase III data with Oral-lyn--was accompanied by a flood in volume. In the US alone, diabetes' costs approach 200 billion, and with FDA approval of Oral-lyn, it's a fair bet that Generex will graduate from the "penny stock" label.

  • Report this Comment On March 16, 2009, at 10:18 AM, razormd wrote:

    ..."penny" stocks, probably more often than not, are scams...case in point is GNBT which for over 10 years has claiming to be developing an oral spray for delivery of medications...but look up the patent and you see that it is a screwball admixture of bile acid and assorted oils...GNBT has done a single experiment demonstrating this crap works any better than simply eating the medication...the ONLY things the company has accomplished is an endless string of losses and empty promises...oh, I forgot, they also accomplished a "death spiral" PIPE -- thanks to which the float has been increasing exponentially...and as if to add insult to injury, the CEO periodically has appeared in interviews wearing a ring with a diamond big enough to choke a horse!...most penny stocks are worth no more than a lottery ticket.

  • Report this Comment On March 16, 2009, at 10:22 AM, razormd wrote:

    ...ack!...error in my previous post -- should read "GNBT has NOT done a single experiment"...NONE!

  • Report this Comment On March 17, 2009, at 11:56 AM, zapzinger wrote:

    Here's a study and link found at the National Institute of Health website: Comparison of Oral Insulin Spray and SubcutaneousRegular Insulin at Mealtime in Type 1 Diabetes.

    "CONCLUSIONS: Regular insulin and Oral-lyn had similar glucodynamic effects in subjects with T1DM receiving twice-daily insulin analogue as baseline therapy. Intensive monitoring and timely corrections with additional snacks, additional sc regular insulin, or Oral-lyn puffs resulted in appropriate glycemic control as assessed by individual daily glycemic responses and, especially, normal preprandial glycemia."

    In other words, Oral-lyn works as well or better than injected insulin--and clinical trails have found the same thing.

    http://www.ncbi.nlm.nih.gov/pubmed/17705693

    Of course Oral-lyn isn't made using "bile salts", but FDA safe micelle forming molecules which allow Oral-lyn to pass through the bucca (cheek) lining. While many drugs have been designed to be used through the skin...the oral route is even more efficient, and that's how Oral-lyn works and why the prospect of an easy FDA approval is good.

    Insulin shots will be a thing of the past.

    The only problems with Oral-lyn to date is that it will take over market share from other insulin companies and it's stock will rip through the hands of short traders attempting to suppress it.

    No wonder they're scared!

  • Report this Comment On March 18, 2009, at 3:08 PM, walkhorse wrote:

    I have followed this stock over the years. I've invested in this stock and I have Diabetes. I will buy this product to eliminate sticking a hypodermic needle into me 4 times a day. My stomach is covered in hematomas from piercing blood vessels.This product will give me back mobility and freedom. When it gets in the U.S. marketplace I will purchase this product.

    Regards,

    walkhorse

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 851379, ~/Articles/ArticleHandler.aspx, 12/5/2009 5:49:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Dumbest Stimulus Plan to Date

Related Tickers

12/4/2009 4:01 PM
DYN $2.02 Up +0.07 +3.59%
Dynegy, Inc. CAPS Rating: ****
NVR $672.91 Up +2.93 +0.44%
NVR, Inc. CAPS Rating: *
Q $3.91 Down -0.02 -0.51%
Qwest Communicatio… CAPS Rating: **
GNBT $0.55 Down -0.01 -1.79%
Generex Biotechnol… CAPS Rating: ***
MIVA $0.22 Down +0.00 +0.00%
MIVA, INC. CAPS Rating: No stars

Community: Investing Wiki

Term Of The Hour

Spin-off: Spin-off is the act of creating a company from a division of a larger parent company.

Want to learn more or edit this definition?
Click here to read more!